Q3 2025 · 13F-HR
RTW INVESTMENTS, LPholdings as filed
Filed 2025-11-14 · accession 0001493215-25-000054
$8.12B
Reported value
74
Positions
2025-09-30
Period end
The Brief · RTW INVESTMENTS, LP · Q3 2025
AI · grounded in 13F
RTW INVESTMENTS, LP closed its position in VRNA for a reduction of $288.6M. The fund also exited its holding in ABT for $60.4M and trimmed its stake in ZLAB by 58.6%. On the buy side, the fund established a new position in COGT worth $49.8M and increased its holding in XNCR by 158.9%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $914.4M | 11.3% | 1,993,687 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $496.7M | 6.12% | 673,497 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $495.5M | 6.11% | 11,372,829 | Common | SOLE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $475.4M | 5.86% | 7,746,415 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $444.2M | 5.47% | 3,084,558 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $382.4M | 4.71% | 5,756,277 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $321.9M | 3.97% | 2,000,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $260.1M | 3.20% | 5,477,561 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $258.3M | 3.18% | 4,424,968 | Common | SOLE |
| 70975L107 | PEN | PENUMBRA INC | $219.5M | 2.70% | 866,499 | Common | SOLE |
| 750491102 | RDNT | RADNET INC | $214.6M | 2.64% | 2,815,544 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $190.7M | 2.35% | 2,025,277 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $188.8M | 2.33% | 3,177,436 | Common | SOLE |
| 863667101 | SYK | STRYKER CORPORATION | $181.1M | 2.23% | 490,000 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $176.9M | 2.18% | 4,869,798 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $152.5M | 1.88% | 7,144,524 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $149.6M | 1.84% | 2,721,158 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $149.1M | 1.84% | 1,062,072 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $135.9M | 1.67% | 1,118,883 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $120.4M | 1.48% | 5,123,525 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $107.8M | 1.33% | 2,712,097 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HLDGS INC | $106.1M | 1.31% | 2,588,831 | Common | SOLE |
| 574795100 | MASI | MASIMO CORP | $100.8M | 1.24% | 683,294 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $98.0M | 1.21% | 3,258,266 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $92.5M | 1.14% | 1,481,033 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $90.7M | 1.12% | 4,543,895 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $90.5M | 1.12% | 202,456 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $79.6M | 0.98% | 5,569,564 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $79.6M | 0.98% | 24,354,291 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $77.7M | 0.96% | 2,291,372 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $75.1M | 0.93% | 8,815,617 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $73.0M | 0.90% | 6,221,054 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $68.5M | 0.84% | 1,701,216 | Common | SOLE |
| 08659B102 | BBNX | BETA BIONICS INC | $65.6M | 0.81% | 3,299,191 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $60.7M | 0.75% | 3,621,996 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $57.7M | 0.71% | 17,687,772 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $55.6M | 0.68% | 2,291,747 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $50.2M | 0.62% | 1,672,356 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $49.9M | 0.61% | 8,707,390 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $49.8M | 0.61% | 3,467,486 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $47.9M | 0.59% | 5,426,306 | Common | SOLE |
| 74834L100 | DGX | QUEST DIAGNOSTICS INC | $47.6M | 0.59% | 250,000 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $40.2M | 0.50% | 863,389 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $37.9M | 0.47% | 1,470,499 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $37.4M | 0.46% | 1,945,649 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $36.6M | 0.45% | 2,890,567 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $36.3M | 0.45% | 872,387 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $34.9M | 0.43% | 6,250,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $29.7M | 0.37% | 350,000 | Common | SOLE |
| 36266G107 | GEHC | GE HEALTHCARE TECHNOLOGIES I | $29.6M | 0.36% | 393,500 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $26.8M | 0.33% | 6,395,732 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $23.6M | 0.29% | 1,362,456 | Common | SOLE |
| 07782B104 | BLTE | BELITE BIO INC | $23.1M | 0.28% | 312,500 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $20.7M | 0.25% | 6,990,806 | Common | SOLE |
| 68572M106 | OBIO | ORCHESTRA BIOMED HLDGS INC | $20.6M | 0.25% | 8,306,063 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $19.7M | 0.24% | 2,679,479 | Common | SOLE |
| 30068X103 | XGN | EXAGEN INC | $18.6M | 0.23% | 1,696,866 | Common | SOLE |
| 42238D107 | HTFL | HEARTFLOW INC | $16.7M | 0.21% | 495,000 | Common | SOLE |
| 88023B103 | TEM | TEMPUS AI INC | $16.1M | 0.20% | 200,000 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $12.5M | 0.15% | 1,449,273 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $11.0M | 0.14% | 3,461,500 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $10.1M | 0.12% | 1,705,960 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $10.1M | 0.12% | 3,125,000 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $8.8M | 0.11% | 2,500,000 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $7.8M | 0.10% | 742,500 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $6.9M | 0.09% | 1,500,000 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $6.6M | 0.08% | 900,000 | Common | SOLE |
| 02008G201 | ALUR | ALLURION TECHNOLOGIES INC | $5.2M | 0.06% | 2,542,603 | Common | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $5.0M | 0.06% | 2,506,102 | Common | SOLE |
| 68170A108 | OMDA | OMADA HEALTH INC | $4.4M | 0.05% | 200,000 | Common | SOLE |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $2.9M | 0.04% | 378,346 | Common | SOLE |
| 45175G207 | IMA | IMAGENEBIO INC | $2.7M | 0.03% | 334,445 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $406,160 | 0.01% | 209,361 | Common | SOLE |
| 77313F114 | RCKTW | ROCKET PHARMACEUTICALS INC | $13,720 | 0.00% | 350,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.